Equipment shortage and overpriced APIs pinch the pharma industry
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The facility is expected to be completed in 2024
Subscribe To Our Newsletter & Stay Updated